Expression of Trk receptors is an important prognostic factor in neuroblastoma (NB) and other cancers. TrkB and its ligand brain-derived neurotrophic factor (BDNF) are preferentially expressed in NB with poor prognosis, conferring invasive and metastatic potential to the tumor cells as well as enhancing therapy resistance. Galectin-1 (Gal-1) has emerged as an interesting cancer target, as it is involved in modulating cell proliferation, cell death and cell migration, all of which are linked to cancer initiation and progression. We previously identified Gal-1 mRNA to be upregulated in patients with aggressive, relapsing NB and found that Gal-1 protein was upregulated in human SY5Y NB cells on activation of ectopically expressed TrkB (SY5Y-TrkB), but not TrkA (SY5Y-TrkA). Here, we report that Gal-1 mRNA levels positively correlated with TrkB expression and anticorrelated with TrkA expression in a cohort of 102 primary NB. Immunohistochemical analyses of 92 primary NB specimens revealed high Gal-1 expression in stromal septae and in neuroblasts. BDNF-mediated activation of TrkB enhanced invasiveness and migration in vitro, which could be impaired by transient transfection using Gal-1-specific siRNA or a neutralizing antibody directed against Gal-1. The addition of recombinant Gal-1 (rGal-1) in the absence of BDNF partially restored migration and invasive capacity. Using the Trk inhibitor K252a, we could show that the upregulation of Gal-1 protein strictly depended on activated TrkB. Our data suggest that targeting Gal-1 might be a promising strategy for the treatment of aggressive NB.
Introduction
Galectin-1 (Gal-1) is a multifunctional protein involved in various aspects of tumorigenesis and has been described as a promising cancer target (reviewed in Liu and Rabinovich (2005) ; Rabinovich (2005) ; Salatino et al. (2008) ). It can act as an extracellular matrix protein to modulate cell adhesion (Hughes, 2001) as well as intracellularly by interaction with H-ras causing Ras membrane anchorage and cell transformation (Paz et al., 2001) . Gal-1 function has been found to be intricately linked to essential biological processes in tumor cells. It regulates complex signaling pathways involved in tumor-host interaction (Juszczynski et al., 2007; Rodig et al., 2008) and angiogenesis (Thijssen et al., 2006) . By forcing activated T cells to undergo apoptosis (He and Baum, 2004) , Gal-1 expression has been hypothesized to contribute to the tumor-immune escape. Inhibition of Gal-1 function resulted in T-cellmediated tumor rejection (Rubinstein et al., 2004) . Gal-1 has been shown to contribute to tumor angiogenesis in a mouse melanoma model (Le Mercier et al., 2008) , and selective peptide inhibitors to Gal-1 have been developed that show profound antiangiogenic activity in vivo (Thijssen et al., 2007) . Intracellularly, Gal-1 can associate with H-ras and direct the transport of farnesylated H-ras to the Golgi apparatus in various systems (Belanis et al., 2008) . Inhibition of H-ras/Gal interaction by small molecule inhibitors, such as farnesylthiosalicylate, (Paz et al., 2001 ) has proved anticancer activity in various model systems and is now proceeding to clinical development.
In neuroblastoma (NB), the most common tumor of childhood, neurotrophin receptors of the Trk family are key players determining biology as well as patient prognosis. Expression of TrkA/NTRK1 is associated with favorable biology and excellent patient outcome, whereas expression of TrkB/NTRK2 correlates with unfavorable tumor biology and poor patient outcome (Nakagawara et al., 1993 (Nakagawara et al., , 1994 . Therefore, proteins that are differentially regulated in TrkA-and TrkBexpressing NBs are excellent candidate targets for NB therapy.
We have developed model systems for differential Trk expression in the neurotrophin receptor null human SH-SY5Y NB cell line by stable transfection with either TrkA or TrkB. In this cell line model, we extensively analysed the consequences of receptor expression and activation on transcriptome and protein levels (Sitek et al., 2005) . Of those proteins regulated both on transcriptome and protein levels, Gal-1 was of special interest as it consistently showed divergent regulation between TrkA-and TrkB-expressing cells. Here, we provide evidence that Gal-1 expression is upregulated by the activation of TrkB, but not by TrkA in NB cells. Furthermore, we show that blocking Gal-1 function reduces the migratory and invasive capacity of NB cells, indicating that Gal-1 is a potential target for the therapy of aggressive NB.
Results
Gal-1 mRNA expression correlates with neurotrophin receptor expression in primary NB As our earlier findings suggested an upregulation of Gal-1 levels in TrkB-but not TrkA-expressing SY5Y NB cells in vitro (Sitek et al., 2005) , we analysed Gal-1 mRNA expression in a cohort of 102 primary NBs. Gal-1 expression correlated significantly with the levels of TrkB expression (P ¼ 4 Â 10
À9
) and was anticorrelated with TrkA expression (P ¼ 6 Â 10
À3
, Figure 1a ). This is in line with the results in our model system, SY5Y, in which Gal-1 protein levels are higher in TrkB-expressing SY5Y cells (SY5Y-TrkB) than in TrkA-expressing SY5Y cells (SY5Y-TrkA) following receptor activation by the respective ligand (Sitek et al., 2005) . In addition, Gal-1 mRNA levels increased on activation of TrkB by BDNF, but not on activation of TrkA by nerve growth factor (NGF) or in the vector control ( Figure 1b) . Furthermore, recombinant Gal-1 (rGal-1) induced Gal-1 mRNA expression only in SY5Y-TrkB, but not in SY5Y-TrkA cells, suggesting a feedback activation loop (Figure 1c) . Interestingly, this effect could be reverted if the sugar-binding capacity of Gal-1 was blocked by the addition of lactose, whereas cell proliferation was not affected by rGal-1 (Figure 1d ). Taken together, Gal-1 expression was found to be tightly linked to TrkB expression in vivo and in vitro.
Gal-1 protein is highly expressed in primary NB To analyse Gal-1 expression in situ, we hybridized a tissue microarray containing 92 primary NBs with a Gal-1-specific antibody. There were distinguishable patterns of Gal-1-staining intensity in the tumor cells ( Figure 2 ) with a trend toward elevated expression in higher tumor stages, but statistical analyses revealed no significant correlation between Gal-1 protein expression and patient survival or clinical parameters, including age at diagnosis, stage or MYCN amplification (data in text only). Interestingly, Gal-1 expression was also high in stromal septae, in particular, in differentiating tumors (Figure 2 ).
Gal-1 contributes to BDNF-mediated invasion of SY5Y-TrkB cells
The invasive capacity of SY5Y-TrkA and SY5Y-TrkB cells was assessed using a Boyden chamber assay. Although neurotrophin receptor activation resulted in very few migrating cells in SY5Y-TrkA and empty vector control, migration of SY5Y-TrkB cells was strongly enhanced on TrkB activation by BDNF (Figure 3a) . The addition of rGal-1 alone modestly enhanced the migratory capacity of TrkB cells, whereas blocking Gal-1 function using a neutralizing anti-Gal-1 antibody strongly reduced BDNF-mediated migration of SY5Y-TrkB cells, but not of SY5Y-TrkA cells or control cells (Figure 3b and data not shown). rGal-1 and BDNF cooperatively induced cell migration in SY5Y-TrkB (Figure 3b , lower right part).
We also aimed to assess whether the intracellular or extracellular function of Gal-1 is required for invasion. For this purpose, we knocked down the intracellular pools of Gal-1 by siRNA and added rGal-1 simultaneously. The downregulation of Gal-1 by siRNA strongly reduced the invasiveness of BDNF-activated TrkB-expressing cells, which could be restored by the addition of rGal-1 (Figure 3c ). In summary, this suggests a strong impact of extracellular Gal-1 on the invasive capacity of TrkBexpressing NB cells. BDNF-mediated upregulation of Gal-1 expression strictly depends on TrkB receptor activation The contribution of an activated and functional TrkBsignaling pathway to the regulation of Gal-1 expression was assessed using K252a, a general inhibitor of Trk signaling. The activation of TrkB by BDNF induced an increased phosphorylation of Akt (p-Akt) in SY5Y-TrkB cells that was inhibited by K252a ( Figure 5 ). Akt activation could be restored only partially by the simultaneous addition of BDNF and K252a. We did not find Akt activation in control-transfected cells (SY5Y-vec) on neurotrophin addition, but only an increase in p-Akt on treatment with K252a. BDNFmediated upregulation of Gal-1 expression in SY5Y-TrkB was abrogated when the TrkB receptor was inhibited by K252a alone or by the simultaneous addition of BDNF and K252a ( Figure 5 ). These findings strongly suggest that Gal-1 upregulation is strictly dependent on a functional TrkB pathway.
Discussion
Aggressiveness defined by tissue invasion and metastasis is a hallmark of cancer cells (Hanahan and Weinberg, 2000) . In NB, several factors have been identified to be associated with aggressive tumor behavior, including deletion or epigenetic silencing of caspase-8 (Teitz et al., 2000; Eggert et al., 2001) , expression of the HGF/c-met axis (Hecht et al., 2004 (Hecht et al., , 2005 as well as expression of full-length TrkB and its cognate ligand BDNF (Matsumoto et al., 1995) . The latter is also associated with amplification of the MYCN oncogene, which is the strongest independent marker of outcome in NB (Nakagawara et al., 1994) . On the other hand, the expressions of the neurotrophin receptors TrkA (Nakagawara et al., 1993) and TrkC (Yamashiro et al., 1997) are found in favorable NBs, with high expression of TrkA being accompanied by massive changes in the transcriptome of NBs (Schramm et al., 2005b) . This biological diversity between TrkA and TrkB expression could also be verified in vitro (Lucarelli et al., 1997; Schramm et al., 2005a) . Taken together, the identification of effector targets differentially regulated between TrkA-and TrkB-expressing NBs could serve as drug targets for NB treatment. We, therefore, screened a cohort of 102 primary NBs for differentially expressed genes between TrkA and TrkB and compared the results with gene and protein lists obtained in an NB cell line model, SY5Y, with ectopic expression of either TrkA or TrkB Sitek et al., 2005) . One of the most promising candidate genes identified in this analysis was Gal-1, which has been suggested as a cancer target before (Rabinovich, 2005; Salatino et al., 2008) . We found a direct and significant correlation of mRNA expression of TrkB and Gal-1 in primary NB, whereas TrkA and Gal-1 expressions were significantly anticorrelated (Figure 1 ). This clearly stresses the importance of our findings in the in vitro model and suggests a functional link between Trk and Gal-1 expressions also in the primary tumors. This is important, because the inhibition of Gal-1 functions by siRNA has been shown to inhibit tumor angiogenesis, which can be accomplished by siRNA (Mathieu et al., 2007) or by a Gal-1-specific peptide (Thijssen et al., 2006) . Gal-1 expression has also been correlated with tumor aggressiveness (Jung et al., 2007; Chiang et al., 2008) . In invasive breast cancer, Gal-1 was found in cancer-associated stromal cells (Jung et al., 2007) , which is in accordance with our findings in NB (Figure 2 ). However, in contrast to the situation in breast cancer, we could not establish a link between stromal Gal-1 expression and NB progression. Nevertheless, the results prompted us to investigate the consequences of modulating Gal-1 functions in our model system. Brain-derived neurotrophic factor (BDNF)-mediated activation of TrkB increased Gal-1 expression on mRNA and protein levels in SY5Y-TrkB cells, but not in neurotrophin-treated SY5Y-TrkA or control-transfected cells, in line with our earlier results in a proteomic study (Sitek et al., 2005) . Therefore, we not only focused on the differences between TrkA-and TrkB-expressing cells but also analysed the consequences of neurotrophin treatment in our model systems. BDNF markedly increased the invasiveness of SY5Y-TrkB cells and this capacity was reduced by neutralizing Gal-1 function (Figure 3b ). rGal-1 alone was not sufficient to induce the full invasive capacity of SY5Y-TrkB cells, suggesting that other BDNF-induced factors are involved in invasion as well. We and others have previously suggested MCSP and c-Met as TrkB-regulated, proinvasive factors in NB (Hecht et al., 2005; Schulte et al., 2005) . Our current findings identify Gal-1 as a third player contributing to TrkB-mediated invasiveness in NB.
As Gal-1 can exert its functions extracellurlarly as well as intracellularly, we conducted a rescue experiment in which the intracellular pools of Gal-1 were depleted by siRNA, and rGal-1 was added simultaneously. (c) Inhibition of BDNF-triggered invasion mediated by an siRNA directed against Gal-1 can be overcome by the addition of recombinant Gal-1 (rGal-1; CTR ¼ control using an unrelated siRNA sequence, NTC ¼ control using transfection reagent only). It was only when the intracellular Gal-1 levels were depleted by a Gal-1-specific siRNA that the addition of rGal-1 significantly increased the number of invading cells (*P ¼ 0.03, t-test). BDNF, brain-derived neurotrophic factor; Gal-1, Galectin-1; rGal-1, recombinant Gal-1.
Although an siRNA directed against Gal-1 prevented the invasion of SY5Y-TrkB cells, this effect could be completely rescued by the addition of rGal-1 (Figure 3c ). This suggests a major importance of extracellular Gal-1 for invasion either in an autocrine or paracrine manner. Similar results were obtained for the migratory capacity of Trk-expressing NB cells. BDNF-induced migration of SY5Y-TrkB cells was strongly reduced in the presence of a siRNA directed against Gal-1 in a scratch assay, whereas neurotrophin-treated SY5Y-TrkA cells or vector control cells were not able to migrate (Figure 4) . Therefore, both the migratory and invasive capacities of SY5Y cells were highly dependent on the activation of TrkB by BDNF, and these functions were strongly modulated by Gal-1.
Furthermore, we analysed the consequences of interfering with BDNF signaling using the Trk-specific small molecule inhibitor, K252a. BDNF-mediated p-Akt was used as a marker for TrkB activation in SY5Y-TrkB cells, in which inhibition of Akt sensitizes to chemotherapy (Ho et al., 2002; Jaboin et al., 2002) . We had shown earlier that the chosen concentration of K252a (100 nM) is sufficient to inhibit Trk phosphorylation in other model systems (Stephan et al., 2008) . Following treatment with K252a, p-Akt was strongly reduced in BDNF-activated SY5Y-TrkB cells, and this could not be seen in neurotrophin-treated SY5Y cells without Galectin-1-mediated NB aggressiveness F Cimmino et al TrkB expression ( Figure 5) . A minor increase in Akt phosphorylation following K252a treatment in the absence of Trk receptors might be attributed to its described effect on serine/threonine protein kinases (Tapley et al., 1992) . As Gal-1 levels also decrease following K252a treatment, we conclude that Gal-1 induction is directly dependent on activated TrkB in SY5Y-TrkB cells. In summary, we have shown that Gal-1 is correlated with the Trk receptor status in primary NB and that Gal-1 is a major effector of TrkB-mediated aggressiveness. Blocking Gal-1 function clearly and strongly reduced the migratory and invasive capacities of TrkBexpressing NB cells. There are already several strategies available to interfere with Gal-1 functions in vivo, including siRNAs and small molecule inhibitors. These should be analysed to evaluate Gal-1 as a target for the treatment of NB.
Materials and methods
Characteristics of stable transfectants and cell culture Full-length TrkB or TrkA cDNA was cloned into the retroviral expression vector, pLNCX, and transfected in human NB SH-SY5Y (SY5Y) cells by electroporation. Stably transfected cells were selected in RPMI medium supplemented with 500 mg/ml geneticin. As negative control, SY5Y cells were transfected with the empty vector (SY5Y-vec). Surviving, drug-resistant SY5Y cells were subcloned to obtain single-cell clonal lines . Cells were maintained in an atmosphere containing 5% CO 2 in RPMI 1640 medium supplemented with 10% fetal bovine serum, antibiotics and geneticin to maintain selection pressure.
Antibodies and reagents
Antihuman Gal-1 goat polyclonal antibody (R&D Systems, Wiesbaden, Germany) was used for immunohistochemical studies and western blotting in a dilution of 1:200 according to established protocols (Cimmino et al., 2007; Schulte et al., 2008a) . Mouse monoclonal anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) antibody (1:2000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as loading control for western blotting as described (Cimmino et al., 2007) . rGal-1 was a gift of Juergen Kuhlmann (Max-PlanckInstitute, Dortmund, Germany). All reagents and chemicals were purchased from Sigma (Steinheim, Germany) or Roth (Karlsruhe, Germany).
siRNA transfection
Cell lines were transiently transfected with siRNAs directed against Gal-1 or with an unrelated control siRNA (NTC) using lipofectamine buffer according to the manufacturer's protocol (Qiagen, Hilden, Germany). An ALEXA-labeled scrambled siRNA (Qiagen) was used to control for transfection efficiency and as a control for Gal-1-mediated effects. Untreated cells and cells transfected with lipofectamine buffer only were included as negative controls.
Cells were plated at 2 Â 10 5 per well onto six-well plates or at 10 Â 10 5 onto twenty-four-well plates (Corning, Lowell, MA, USA) on the day before transfection. The siRNA was transfected at day 1, and total RNA and protein were extracted at day 4. The knockdown efficacy was monitored by reverse transcriptase PCR and by western blotting (Supplementary Figure 1) .
Western blotting
Cells were washed in cold phosphate-buffered saline and lysed in radio immunoprecipitation assay buffer, supplemented with protease inhibitors (Roche, Penzberg, Germany), as described earlier . Cell lysates (20 mg) were electrophoresed on a 4-15% polyacrylamide gel (Invitrogen, Carlsbad, CA, USA) and transferred onto nitrocellulose membranes (Millipore, Schwalbach, Germany). After 1 h blocking with 5% dry fat milk in phosphate-buffered saline containing 0.02% Tween-20, the membranes were incubated with the primary antibody overnight at 4 1C and with the secondary antibody for 1 h at room temperature. The bands were visualized with enhanced chemiluminescence plus reagent (GE Healthcare, Munich, Germany).
Cell proliferation analysis
Ten thousand cells per well were seeded in 96 multiwell plates. After 24 h, the cells were treated with the respective neurotrophins (NGF 100 ng/ml, BDNF 50 ng/ml), or rGal-1 (2 mg/ml). Metabolic activity as a surrogate marker for cell proliferation of treated samples was assessed after 24 h using the MTT (3-(4,5-dimethylthiazol-2-yl), 5-diphenyltetrazolium bromide) assay. Cell vitality of siRNA-transfected cells was assessed 72 h after transfection. Each value represents six replicates, and each experiment was repeated at least two times.
Reverse transcriptase PCR and microarray analyses
Total RNA from NB cell lines or from 102 primary, untreated NB tumor samples was prepared using Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription, labeling of total RNA and subsequent hybridization to Affymetrix U133v2 chips were carried out according to the manufacturer's protocols and as described earlier (Schulte et al., , 2008b . Relative quantification of Gal-1 mRNA expression was achieved using Taqman Assay Hs00355202_m1 (Applied Biosystems, Foster City, CA, USA) and the DCt method. All assays were carried out in triplicate. mRNA expression was normalized to the averaged GAPDH expression in each sample.
Cell invasion assay
Cell invasiveness was determined using Matrigel invasion chamber inserts (24-well format with 8 mm pores, BD Biosciences, Heidelberg, Germany). Eighty thousand cells were seeded onto the upper chamber in RPMI 1640 medium containing 5% fetal calf serum. siRNA-transfected cells were seeded at day 4 after transfection. The medium in the lower chamber contained 15% fetal calf serum in RPMI 1640 with or without the respective neurotrophins (NGF 100 ng/ml, BDNF 50 ng/ml). rGal-1 (2 mg/ml) or antiGal-1 neutralizing antibody (1:500) or isotype immunoglobulin-G control were added once at the beginning of the experiment to the upper compartment. Cells migrating to the lower membrane surface were stained with hematoxylin/eosin after 24 h. Cells were counted in three representative areas per membrane at Â 40 magnification using a light microscope. The experiments were carried out in duplicate and two independent sets of experiments for each type of invasion assay were carried out.
